Visit us at booth #6064 from May 11th-14th during Immunology 2023 in Washington, DC
Mapping Human Immunity
Mapping Human Immunity
Serimmune is an immune intelligence company that decodes the breadth and complexity of human antibody response, empowering discovery projects through a universal serology assay that identifies disease-specific epitopes across proteins and entire proteomes.
Introducing Immune Profiling Services
SERA Platform Used to Identify Features of Long COVID
Serimmune Announces Use of Its SERA Platform in Study
Serimmune’s proprietary Serum Epitope Repertoire Analysis (SERA) technology platform was one of the methods used to analyze the biological processes associated with the development and persistence of Long COVID symptoms, such as fatigue, brain fog and malaise.
Machine Learning to Track Your Antibodies
Machine Learning to Track Your Antibodies
Serimmune’s at-home tests compare your “epitope repertoire” against known cases, for more accurate profiling of everything from COVID-19 to Lyme disease to Epstein-Barr.
Broad Serosurveillance Using SERA Technology
Broad Serosurveillance Using SERA Technology
View our webinar walking through the use of SERA in Broad Serosurveillance and its use as a tool for research applications.
What We Do
We offer a discovery service to academia, government and industry through the Serimmune universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases - all in a single assay.
How We Do It
Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next-generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Through this, we gain a broad view of an individual’s environmental exposures and the unique immune responses to these exposures in disease and health.
Why We Do It
Serimmune was founded on the belief that the information coded in the individual’s functional antibody repertoire is key to understanding human disease. To fulfill this vision, we created a technology for building and interpreting a dynamic map of human immunity which continually evolves to map interactions between functional antibody repertoire and human disease. Linkages between antibody response to pathogens have been shown in oncology, autoimmune, infectious, neurodegenerative, and other complex diseases.
Immuno-Therapeutics
Vaccines
Target Discovery
Serimmune Biomarker Discovery Service
Learn about Serimmune’s SERA platform which combines large biological libraries, NGS, and custom bioinformatics to unlock the Circulating Antibody Repertoire to achieve hypothesis free serology.
Neutralizing Epitopes
Biomarkers of Response
Events

Resolve the challenges of immunogenicity testing and risk assessment during preclinical and clinical development, bioassay design & analysis, and how to manipulate the immune system for therapeutic advantage
Immunogenicity & Bioassay Summit
October 2nd-5th
Washington, D.C.
mRNA Cancer Vaccine Summit
October 10th-12th
Boston, MA

Unite with mRNA cancer vaccine, oncology and immune-oncology leaders and stay up to date about these innovative cancer therapies.

Advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
Join us at booth #334!
SITC 2023
November 1st-5th
San Diego, CA
Vaccines Summit 2023
November 13th-15th
Boston, MA

Next-generation vaccines treatment and diagnostics that save lives.
You look forward to seeing you at our booth!
In the News
Serimmune